Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
bristol-myers squibb
clinical trials
gilead sciences
3
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
nonalcoholic steatohepatitis
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
aducanumab
affordable care act
alzheimer's disease
biogen
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
genfit
indiana blog main
indiana top stories
johnson & johnson
madrigal pharmaceuticals
nash
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
viking therapeutics
wisconsin blog main
wisconsin top stories
What
drug
nash
3
×
bio
biogen’s
new
news
roundup
aducanumab
alzheimer’s
amyloid
angst
approval
approved
bagged
billions
biogen
biopharmaceutical
brammer
companies
convo
data
disease
earlier
effects
failure
failures
fatty
felt
horizon
intercept
known
littered
liver
lost
marketed
medicine
nonalcoholic
price
remains
ripple
Language
Current search:
nash
×
" gilead sciences "
×
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug